Skip to content

US FDA Approves Vilazodone for MDD

January 24, 2011

The United States Food and Drug Administration approved vilazodone (Viibryd, Trovis Pharmaceuticals) for the treatment of major depressive disorder (MDD). The recommended starting dose is 10 mg QD for the first 7 days. The dosage can then be titrated to a maximum of 40 mg QD.

Approval was based on two, 8-week randomized, double-blind, placebo-controlled trials in 869 adults (436 received vilazodone; 433 received placebo) between 18–70 years of age meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Revised criteria for MDD. In both studies, the Montgomery-Asberg Depression Rating Scale was used to assess all of the patients’ depressive symptoms. By study endpoint, vilazodone was found to be superior to placebo in terms of improving the patients’ depressive symptoms.

The most common adverse events (those occurring in greater than or equal to 5% of patients) were diarrhea, nausea, vomiting, and insomnia.

For more information on vilazodone, please consult the medication’s full prescribing information (www.viibryd.com). —Christopher Naccari

Advertisements

From → FDA Report

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: